Novel bispecific nanobody mitigates experimental intestinal inflammation in mice by targeting TNF‐α and IL‐23p19 bioactivities
Clinical and Translational Medicine · 2024
DOI: 10.1002/ctm2.1636 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2024. Verfasst von Jiewen Wang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Frontiers Science Center for Synthetic Biology and Key Laboratory of Systems Bioengineering (Ministry of Education), School of Chemical Engineering a…. Hauptthemen laut MEDLINE: Colitis, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Project, Science and Technology Program of Tianjin, China, China-CEEC Joint Education Project.
Abstract (Originalsprache)
Background
Inflammatory bowel diseases (IBDs) pose significant challenges in terms of treatment non‐response, necessitating the development of novel therapeutic approaches. Although biological medicines that target TNF‐α (tumour necrosis factor‐α) have shown clinical success in some IBD patients, a substantial proportion still fails to respond.
Methods
We designed bispecific nanobodies (BsNbs) with the ability to simultaneously target human macrophage‐expressed membrane TNF‐α (hmTNF‐α) and IL‐23. Additionally, we fused the constant region of human IgG1 Fc (hIgG1 Fc) to BsNb to create BsNb‐Fc. Our study encompassed in vitro and in vivo characterization of BsNb and BsNb‐Fc.
Results
BsNb‐Fc exhibited an improved serum half‐life, targeting capability and effector function than BsNb. It's demonstrated that BsNb‐Fc exhibited superior anti‐inflammatory effects compared to the anti‐TNF‐α mAb (infliximab, IFX) combined with anti‐IL‐12/IL‐23p40 mAb (ustekinumab, UST) by Transwell co‐culture assays. Notably, in murine models of acute colitis brought on by 2,4,6‐trinitrobenzene sulfonic acid(TNBS) and dextran sulphate sodium (DSS), BsNb‐Fc effectively alleviated colitis severity. Additionally, BsNb‐Fc outperformed the IFX&UST combination in TNBS‐induced colitis, significantly reducing colon inflammation in mice with colitis produced by TNBS and DSS.
Conclusion
These findings highlight an enhanced efficacy and improved biostability of BsNb‐Fc, suggesting its potential as a promising therapeutic option for IBD patients with insufficient response to TNF‐α inhibition. Key points A bispecific nanobody (BsNb) was created to target TNF‐α and IL‐23p19, exhibiting high affinity and remarkable stability. BsNb‐Fc inhibited the release of cytokines in CD4+T cells during co‐culture experiments. BsNb‐Fc effectively alleviated colitis severity in mouse model with acute colitis induced by DSS or TNBS, outperforming the IFX&UST combination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Frontiers Science Center for Synthetic Biology and Key Laboratory of Systems Bioengineering (Ministry of Education), School of Chemical Engineering and Technology, Tianjin University, Tianjin, China.
- Center for Inflammatory Bowel Disease Research and Department of Gastroenterology, The Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
- Laboratory for Environmental and Life Sciences, University of Nova Gorica, Nova Gorica, Slovenia.
- Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Tianjin Medical University, Tianjin, China.
- Department of Gastroenterology, Peking University First Hospital, Beijing, China.
- Department of Gastroenterology, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
ORCID-Profile: Huiying Lu, Zhanju Liu, He Huang
Förderung
- National Key Research and Development Project
- Science and Technology Program of Tianjin, China
- China-CEEC Joint Education Project
- Major State Basic Research Development Program of the Natural Science Foundation of Shandong Province in China
- National Natural Science Foundation of China
- Independent Innovation Foundation of Tianjin University
Zitieren
APA
Wang, J., Kang, G., Lu, H., de Marco, A., Yuan, H., Feng, Z., Gao, M., Wang, X., Wang, H., Zhang, X., Wang, Y., Zhang, M., Wang, P., Feng, Y., Liu, Z., Cao, X., & Huang, H. (2024). Novel bispecific nanobody mitigates experimental intestinal inflammation in mice by targeting TNF‐α and IL‐23p19 bioactivities. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.1636
Vancouver
Wang J, Kang G, Lu H, de Marco A, Yuan H, Feng Z, et al. Novel bispecific nanobody mitigates experimental intestinal inflammation in mice by targeting TNF‐α and IL‐23p19 bioactivities. Clinical and Translational Medicine. 2024. doi:10.1002/ctm2.1636
BibTeX
@article{Wang2024,
author = {Wang, Jiewen and Kang, Guangbo and Lu, Huiying and de Marco, Ario and Yuan, Haibin and Feng, Zelin and Gao, Mengxue and Wang, Xiaoli and Wang, Huahong and Zhang, Xiaolan and Wang, Yuli and Zhang, Miao and Wang, Ping and Feng, Yuanhang and Liu, Zhanju and Cao, Xiaocang and Huang, He},
title = {Novel bispecific nanobody mitigates experimental intestinal inflammation in mice by targeting TNF‐α and IL‐23p19 bioactivities},
journal = {Clinical and Translational Medicine},
year = {2024},
doi = {10.1002/ctm2.1636}
}
EUVIMED